156 related articles for article (PubMed ID: 29204994)
1. Ophthalmic Application of Anti-VEGF Therapy.
Lai TYY; Cheung CMG; Mieler WF
Asia Pac J Ophthalmol (Phila); 2017; 6(6):479-480. PubMed ID: 29204994
[No Abstract] [Full Text] [Related]
2. A New Era in Reducing Treatment Burden in Retinal Disease.
Retina; 2021 Apr; 41(Suppl 1):S1-S12. PubMed ID: 33787534
[No Abstract] [Full Text] [Related]
3. Inhibiting angiogenesis in retinoblastoma.
Apte RS; Harbour JW
Ophthalmic Res; 2007; 39(4):188-90. PubMed ID: 17556838
[No Abstract] [Full Text] [Related]
4. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
5. Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases.
Teng L; Sun Y; Teng S; Hui P
J Biomed Mater Res A; 2024 Feb; 112(2):296-306. PubMed ID: 37850566
[TBL] [Abstract][Full Text] [Related]
6. Lucentis
Eye (Lond); 2017 Aug; 31(S2):S18-S20. PubMed ID: 28845845
[No Abstract] [Full Text] [Related]
7. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
8. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy in the anti-VEGF era.
Fine HF
Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
[TBL] [Abstract][Full Text] [Related]
10. VEGF inhibitors for AMD and diabetic macular edema.
Med Lett Drugs Ther; 2015 Mar; 57(1464):41-2. PubMed ID: 25758545
[No Abstract] [Full Text] [Related]
11. Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration.
Ringeisen AL; Parke DW; Dev S
Int Ophthalmol Clin; 2019; 59(1):127-135. PubMed ID: 30585922
[No Abstract] [Full Text] [Related]
12. [Anti-VEGF: one drug for different conditions?].
Cohen SY; Massin P; Souied E
J Fr Ophtalmol; 2013 Jan; 36(1):2-4. PubMed ID: 23290491
[No Abstract] [Full Text] [Related]
13. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
Micieli JA; Santiago P; Brent MH
Acta Ophthalmol; 2011 Feb; 89(1):e99-100. PubMed ID: 19925526
[No Abstract] [Full Text] [Related]
14. Evolving multidimensional pharmacological approaches to CNV therapy in AMD.
Ehrenberg M; Benny O
Curr Eye Res; 2018 Feb; 43(2):147-154. PubMed ID: 29111834
[TBL] [Abstract][Full Text] [Related]
15. Paracentesis before intravitreal injection of bevacizumab.
Tsui YP; Chiang CC; Tsai YY
Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
[No Abstract] [Full Text] [Related]
16. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
17. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
18. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
Querques G
Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
[No Abstract] [Full Text] [Related]
19. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
20. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
la Cour M
Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202
[No Abstract] [Full Text] [Related]
[Next] [New Search]
